Literature DB >> 29121340

HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Dagmar E Ehrnhoefer1, Amber L Southwell1, Meenalochani Sivasubramanian1, Xiaofan Qiu1, Erika B Villanueva1, Yuanyun Xie1, Sabine Waltl1, Lisa Anderson1, Anita Fazeli1, Lorenzo Casal1, Boguslaw Felczak1, Michelle Tsang1, Michael R Hayden1.   

Abstract

Oxidative stress is a prominent feature of Huntington disease (HD), and we have shown previously that reduced levels of hace1 (HECT domain and Ankyrin repeat containing E3 ubiquitin protein ligase 1) in patient striatum may contribute to the pathogenesis of HD. Hace1 promotes the stability of Nrf2 and thus plays an important role in antioxidant response mechanisms, which are dysfunctional in HD. Moreover, hace1 overexpression mitigates mutant huntingtin (mHTT)-induced oxidative stress in vitro through promotion of the Nrf2 antioxidant response. Here, we show that the genetic ablation of hace1 in the YAC128 mouse model of HD accelerates motor deficits and exacerbates cognitive and psychiatric phenotypes in vivo. We find that both the expression of mHTT and the ablation of hace1 alone are sufficient to cause deficits in astrocytic mitochondrial respiration. We confirm the crucial role of hace1 in astrocytes in vivo, since its ablation is sufficient to cause dramatic astrogliosis in wild-type FVB/N mice. Astrogliosis is not observed in the presence of mHTT but a strong dysregulation in the expression of astrocytic markers in HACE1-/- x YAC128 striatum suggests an additive effect of mHTT expression and hace1 loss on this cell type. HACE1-/- x YAC128 mice and primary cells derived from these animals therefore provide model systems that will allow for the further dissection of Nrf2 pathways and astrocyte dysfunction in the context of HD.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29121340      PMCID: PMC5886116          DOI: 10.1093/hmg/ddx394

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  72 in total

Review 1.  Metabolic control through the PGC-1 family of transcription coactivators.

Authors:  Jiandie Lin; Christoph Handschin; Bruce M Spiegelman
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

2.  Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

Authors:  Amber L Southwell; Sonia Franciosi; Erika B Villanueva; Yuanyun Xie; Laurie A Winter; Janaki Veeraraghavan; Alan Jonason; Boguslaw Felczak; Weining Zhang; Vlad Kovalik; Sabine Waltl; George Hall; Mahmoud A Pouladi; Ernest S Smith; William J Bowers; Maurice Zauderer; Michael R Hayden
Journal:  Neurobiol Dis       Date:  2015-02-03       Impact factor: 5.996

3.  Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.

Authors:  Marcus J Calkins; Rebekah J Jakel; Delinda A Johnson; Kaimin Chan; Yuet Wai Kan; Jeffrey A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

4.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

5.  PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

Authors:  Taiji Tsunemi; Travis D Ashe; Bradley E Morrison; Kathryn R Soriano; Jonathan Au; Ruben A Vázquez Roque; Eduardo R Lazarowski; Vincent A Damian; Eliezer Masliah; Albert R La Spada
Journal:  Sci Transl Med       Date:  2012-07-11       Impact factor: 17.956

6.  Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Authors:  Ulziibat P Shirendeb; Marcus J Calkins; Maria Manczak; Vishwanath Anekonda; Brett Dufour; Jodi L McBride; Peizhong Mao; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2011-10-13       Impact factor: 6.150

7.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

8.  Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration.

Authors:  Kira M Holmström; Liam Baird; Ying Zhang; Iain Hargreaves; Annapurna Chalasani; John M Land; Lee Stanyer; Masayuki Yamamoto; Albena T Dinkova-Kostova; Andrey Y Abramov
Journal:  Biol Open       Date:  2013-06-20       Impact factor: 2.422

Review 9.  The emerging role of Nrf2 in mitochondrial function.

Authors:  Albena T Dinkova-Kostova; Andrey Y Abramov
Journal:  Free Radic Biol Med       Date:  2015-05-11       Impact factor: 7.376

10.  HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response.

Authors:  Barak Rotblat; Amber L Southwell; Dagmar E Ehrnhoefer; Niels H Skotte; Martina Metzler; Sonia Franciosi; Gabriel Leprivier; Syam Prakash Somasekharan; Adi Barokas; Yu Deng; Tiffany Tang; Joan Mathers; Naniye Cetinbas; Mads Daugaard; Brian Kwok; Liheng Li; Christopher J Carnie; Dieter Fink; Roberto Nitsch; Jason D Galpin; Christopher A Ahern; Gerry Melino; Josef M Penninger; Michael R Hayden; Poul H Sorensen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

View more
  7 in total

1.  Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.

Authors:  Nicholas S Caron; Raul Banos; Christopher Yanick; Amirah E Aly; Lauren M Byrne; Ethan D Smith; Yuanyun Xie; Stephen E P Smith; Nalini Potluri; Hailey Findlay Black; Lorenzo Casal; Seunghyun Ko; Daphne Cheung; Hyeongju Kim; Ihn Sik Seong; Edward J Wild; Ji-Joon Song; Michael R Hayden; Amber L Southwell
Journal:  J Neurosci       Date:  2020-12-11       Impact factor: 6.167

2.  HACE1, an E3 Ubiquitin Protein Ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus Infection-Induced Oxidative Stress by Promoting Nrf2 Activity.

Authors:  Binod Kumar; Arunava Roy; Kumari Asha; Neelam Sharma-Walia; Mairaj Ahmed Ansari; Bala Chandran
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

3.  meQTL and ncRNA functional analyses of 102 GWAS-SNPs associated with depression implicate HACE1 and SHANK2 genes.

Authors:  Diana M Ciuculete; Sarah Voisin; Lara Kular; Jörgen Jonsson; Mathias Rask-Andersen; Jessica Mwinyi; Helgi B Schiöth
Journal:  Clin Epigenetics       Date:  2020-07-02       Impact factor: 6.551

Review 4.  Role of Optineurin in the Mitochondrial Dysfunction: Potential Implications in Neurodegenerative Diseases and Cancer.

Authors:  Robert Weil; Emmanuel Laplantine; Shannel Curic; Pierre Génin
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

Review 5.  Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations.

Authors:  Dayan Sun; Yang Wei; Hong-Xiang Zheng; Li Jin; Jiucun Wang
Journal:  Front Mol Biosci       Date:  2019-11-15

Review 6.  Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.

Authors:  Morgan E Rook; Amber L Southwell
Journal:  BioDrugs       Date:  2022-03-07       Impact factor: 7.744

7.  Physiopathological Bases of the Disease Caused by HACE1 Mutations: Alterations in Autophagy, Mitophagy and Oxidative Stress Response.

Authors:  Olatz Ugarteburu; Marta Sánchez-Vilés; Julio Ramos; Tamara Barcos-Rodríguez; Gloria Garrabou; Judit García-Villoria; Antonia Ribes; Frederic Tort
Journal:  J Clin Med       Date:  2020-03-26       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.